CSIMarket
 


Mymd Pharmaceuticals Inc   (MYMD)
Other Ticker:  
 

Cumulative Mymd Pharmaceuticals Inc 's Quick Ratio for Trailing Twelve Months Period

MYMD's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

MYMD Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 231.66 % -16.99 % -35.59 % 173.98 % -16.37 %
Y / Y Cash & cash equivalent Growth 19.6 % 106.85 % 69.22 % -58.16 % -53.93 %
Quick Ratio for Trailing Twelve Months Period 3.29 4.69 3.75 2.76 4.2
Total Ranking # 711 # 581 # 770 # 1111 # 861
Seq. Current Liabilities Growth 141.46 % 51.45 % -42.38 % 57.41 % -39.57 %
Seq. Cash & cash equivalent Growth -27.13 % -25.22 % 221.52 % -31.74 % 26.03 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to doubling in Current Liabilities in the III. Quarter to $6 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 3.29 below Mymd Pharmaceuticals Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within In Vitro & In Vivo Diagnostic Substances industry 8 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Mymd Pharmaceuticals Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about MYMD
Quick Ratio MYMD in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 9
Sector # 620
S&P 500 # 1122


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
8.99 3.93 0.59
(Dec 31 2021)   (Sep 30 2017)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within In Vitro & In Vivo Diagnostic Substances Industry Quick Ratio for Trailing Twelve Months Period
Intellia Therapeutics Inc   8.42 
Heska Corporation  4.17 
Biomerica Inc   4.00 
Mymd Pharmaceuticals Inc   2.57 
Achieve Life Sciences Inc   2.44 
Neogen Corporation  2.20 
Lantheus Holdings Inc   2.09 
Oncocyte Corporation  2.04 
Aspira Women s Health Inc   1.90 
Cardio Diagnostics Holdings Inc   1.61 
Immucell Corp  1.25 
Meridian Bioscience Inc   1.14 
Alpha Teknova Inc   0.93 
Volitionrx Limited  0.82 
Myriad Genetics Inc   0.73 
Nymox Pharmaceutical Corporation  0.68 
Quotient Limited  0.66 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com